NPSP News Alert NPS Pharmaceuticals (NPSP) 35.06 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
NPS Pharmaceuticals (NPSP) 35.06 $NPSP

NPS Pharmaceuticals Has Returned 24.7% Since SmarTrend Recommendation (NPSP)
Comtex SmarTrend(R) - Mon Dec 22, 9:16AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 2 months, NPS Pharmaceuticals has returned 24.68% as of today's recent price of $35.03.
NPSP: 35.06 (+1.18)

NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:30PM CST
A report from Bloomberg indicated that the Shire is considering a potential acquisition of the NPS Pharma.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18), ABBV: 66.21 (+1.86)

Nasdaq stocks posting largest percentage increases
AP - Thu Dec 18, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CERS: 6.49 (+0.29), PTRY: 36.78 (+0.28), DRIV: 24.49 (+0.09), MTLS: 9.12 (-0.08), VOLC: 17.95 (+0.02), NPSP: 35.06 (+1.18), NYNY: 7.89 (+0.32), XNCR: 16.83 (+0.77), AREX: 6.98 (-0.11)

Market Driven by Key Factors: Complementary Research on General Mills, The Pantry, Approach Resources, NPS and Digital River
PR Newswire - Thu Dec 18, 8:14AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including General Mills (NYSE: GIS), The Pantry (NASDAQ: PTRY), Approach Resources (NASDAQ: AREX), NPS (NASDAQ: NPSP), and Digital River (NASDAQ: DRIV). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
DRIV: 24.49 (+0.09), PTRY: 36.78 (+0.28), NPSP: 35.06 (+1.18), GIS: 54.31 (-0.10), AREX: 6.98 (-0.11)

NPS Pharmaceuticals (NPSP) Jumps: Stock Moves 18.5% Up - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 7:51AM CST
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 19% on the day.
SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18)

After Yesterday's Rally of 18.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Dec 17, 4:40PM CST
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $30.26 to a high of $37.50. Yesterday, the shares gained 18.5%, which took the trading range above the 3-day high of $32.42 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NPSP: 35.06 (+1.18)

Why NPS Pharmaceuticals, Inc. Stock Lifted Off in Midday Trading
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 17, 1:30PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NPS Pharmaceuticals , a biopharmaceutical...
SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18), ABBV: 66.21 (+1.86)

NPS Pharma up 20% on takeover buzz
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 10:21AM CST

SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18)

NPS Pharmaceuticals (NPSP) Marked As A Barbarian At The Gate
at The Street - Wed Dec 17, 10:01AM CST
Trade-Ideas LLC identified NPS Pharmaceuticals (NPSP) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
NPSP: 35.06 (+1.18)

Critical Alerts For Linn Energy, Delta Airlines, Herbalife, Ambarella and NPS Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Dec 17, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LINE, DAL, HLF, AMBA and NPSP.
AMBA: 52.05 (+0.72), HLF: 37.98 (+0.20), DAL: 48.05 (+0.92), NPSP: 35.06 (+1.18), LINE: 10.93 (-0.32)

NPS Pharmaceuticals Shares Up 11.3% Since SmarTrend's Buy Recommendation (NPSP)
Comtex SmarTrend(R) - Fri Dec 12, 5:01PM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 2 months, NPS Pharmaceuticals has returned 11.34% as of today's recent price of $31.28.
NPSP: 35.06 (+1.18)

Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 9.63 (+0.21), NPSP: 35.06 (+1.18), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)

Wedbush Securities' David Nierengarten On Genetic Cures For Disease: Impossible Dream Come True?
Life Sciences Report - at Seeking Alpha - Thu Dec 11, 1:57PM CST
Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients. In this interview with The Life Sciences Report , David Nierengarten of...
BLUE: 88.76 (+3.23), AGTC: 20.96 (+0.22), NPSP: 35.06 (+1.18)

18.7% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Fri Dec 05, 5:10PM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 2 months, NPS Pharmaceuticals has returned 18.70% as of today's recent price of $33.35.
NPSP: 35.06 (+1.18)

NPS Pharma to Present at Oppenheimer Healthcare Conference
Business Wire - Thu Dec 04, 7:10AM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 9:45 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS Pharma website at http://ir.npsp.com/events.cfm.
NPSP: 35.06 (+1.18)

European Medicines Agency Validates Marketing Authorization Application for Natpar(R) (parathyroid hormone (rDNA)) in Hypoparathyroidism
Business Wire - Tue Dec 02, 8:16AM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Medicines Agency (EMA) has validated and initiated its review of the company's marketing authorization application (MAA) for Natpar(R) (parathyroid hormone (rDNA)) for the treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH). If approved, Natpar would be the first and only PTH replacement therapy in Europe for patients with Hypoparathyroidism.
NPSP: 35.06 (+1.18)

22.6% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Fri Nov 28, 11:04AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 1 month, NPS Pharmaceuticals has returned 22.62% as of today's recent price of $34.45.
NPSP: 35.06 (+1.18)

NPS Pharmaceuticals' SBS Drug Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 3:45PM CST
NPS Pharmaceuticals (NPSP) announced that teduglutide has received orphan drug designation in Japan for the treatment of short bowel syndrome.
LCI: 42.29 (+1.79), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), NPSP: 35.06 (+1.18)

NPS Pharma to Present at Deutsche Bank BioFEST Conference
Business Wire - Tue Nov 25, 3:10PM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is scheduled to present at the 2014 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 2, 2014 at 9:55 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS Pharma website at http://ir.npsp.com/events.cfm.
NPSP: 35.06 (+1.18), DB: 30.95 (+0.04)

Post Earnings Update: NPS Pharmaceuticals Has Climbed 18.9% Higher in Past 2 Weeks (NPSP)
Comtex SmarTrend(R) - Mon Nov 24, 9:23AM CST
14 days ago, on November 10th, 2014, NPS Pharmaceuticals (NASDAQ:NPSP) reported its earnings. Analysts, on average, expected earnings of $0.02 per share on sales of $59.8 million. NPS Pharmaceuticals actually reported a loss of $0.02 per share on sales of $57.2 million, missing EPS estimates by $0.04 and missing revenue estimates by $2.6 million. Shares of NPS Pharmaceuticals have climbed from $26.91 to $32.00, representing a gain of 18.9% since the company reported earnings 14 days ago.
NPSP: 35.06 (+1.18)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 101

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 103

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 29

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 76

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
Trump's Reagan Forum Speech Puts Defense in Focus Again

Updated Category News Views 118

A December podium in Simi Valley has suddenly become a market-relevant appointment. The Ronald Reagan Presidential Foundation and Institute says President Donald J. Trump will deliver the keynote at the 2026 Reagan National Defense Forum on Friday, December 4, at 3:00 p.m. Pacific time, or 6:00 p.m. Eastern. That is the whole hard fact pattern so far. No agenda, no...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 99

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 73

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 62

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading

Top 5 Most Recently Viewed Articles

Redsun Properties Faces $350 Million Bond Payment Crisis Ahead

Updated Category News Views 189

Redsun Properties Announces Inability to Pay Bond Chinese property developer Redsun Properties has communicated its inability to meet a $350 million bond payment, which is due shortly. This situation has raised considerable concern within the financial markets as it highlights the ongoing issues facing property developers in China. Details of the Bond Issue This bond,...

Continue Reading
Etruscus Resources Unveils Promising Findings at Zappa Target

Updated Category News Views 135

Etruscus Resources Makes Progress at Key Exploration Sites Etruscus Resources Corp. is thrilled to report on the encouraging findings from its exploration program at the Rock & Roll Property. This property is situated in the Golden Triangle region, known for its wealth of mineral resources. The exploration program, which included comprehensive rock sampling and geological...

Continue Reading
MetLife's Strategic Focus: Navigating Q3 2024 Earnings

Updated Category News Views 1091

MetLife Announces Q3 2024 Results and New Frontier Strategy In the third quarter of 2024, MetLife, Inc. (MET) reported adjusted earnings of $1.4 billion, translating to $1.93 per share. This reflects a decline from previous year figures, yet a 12% year-to-date increase in adjusted earnings per share (EPS) excluding notable items. The insurance powerhouse has seen positive...

Continue Reading
VEON Invests in Ukraine: Commitment to Digital Growth

Updated Category News Views 125

VEON's Commitment to Investing in Ukraine VEON Ltd. (NASDAQ: VEON), a leading global digital operator, has recently made significant news with its promise to enhance Ukraine’s telecommunications infrastructure. In collaboration with its fully-owned subsidiary, Kyivstar, VEON participated in the 2024 Yalta European Strategy (YES) Annual Meeting. At this event, the focus...

Continue Reading
Expanding Diabetes Care: From Monitoring to Change

Updated Category News Views 44

Breaking Ground at the AGP & DTx Summit Diabetes management ain't what it used to be, and the 4th AGP & DTx Summit in Shenzhen gave us an eyeful of change. Under the banner "Beyond Glucose," experts from all corners came together to talk shop about Continuous Glucose Monitoring (CGM) and how it might shake up diabetes care. CGM: More Than a Gadget See, CGM's not just a...

Continue Reading